TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy

AIDS

Volumn 16, Issue 15, 2002, Pages 2013-2018

  Maher, Bridget ^a   Alfirevic, Ana ^a   Javier Vilar, F ^a   Wilkins, Edmund G L ^a   Park, B Kevin ^a   Pirmohamed, Munir ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Antiretroviral therapy; Cytokines; Lipodystrophy; Molecular biology; Protease inhibitors

Indexed keywords

ABACAVIR; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; RISK FACTOR;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037131198     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200210180-00005     Document Type: Article

References (41)

1. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
2. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000, 356:1423-1430.
3. Safrin S, Grunfeld C. Fat distribution and metabolic changes in patients with HIV infection. AIDS 1999, 13:2493-2505.
4. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet 1998, 351:867-870.
5. Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998, 12:F37-39.
6. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51-58.
7. Carr A, Cooper DA. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998, 339:1296-1296.
8. Miller KK, Daly PA, Sentochnik D, et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998, 27:68-72.
9. Roth VR, Kravcik S, Angel JB. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis 1998, 27:65-67.
10. Stricker RB, Goldberg B. Fat accumulation and HIV-1 protease inhibitors. Lancet 1998, 352:1392.
11. Madge S, Kinloch-de-Loes S, Mercey D, Johnson MA, Weller IV. Lipodystrophy in patients naive to HIV protease inhibitors. AIDS 1999, 13:735-737.
12. Carr A, Miller J, Law M, Cooper DA. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome. AIDS 2000, 14:F25-F32.
13. Saint-Marc T, Partisani M, Poizot-Martin I, et al. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy. AIDS 1999, 13:1659-1667.
14. Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998, 351:1881-1883.
15. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse- transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999, 354:1112-1115.
16. Moyle G. Toxicity of antiretroviral nucleoside and nucleotide analogues: is mitochondrial toxicity the only mechanism? Drug Saf 2000, 23:467-481.
17. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001, 6:9-20.
18. Kotler DP. The epidemiology and pathogenesis of lipodystrophy in HIV disease: an update. The PRN Notebook 2000, 5:9-13.
19. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999, 353:2093-2099.
20. Reus S, Arroyo E, Boix V, Portilla J. Lipodystrophy and hyperglycemia produced by protease inhibitors. Ann Med Interna 2000, 17:123-126.
21. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000, 14:1309-1316.
22. Flier JS. Pushing the envelope on lipodystrophy. Nat Genet 2000, 24:103-104.
23. Molvig J, Baek L, Christensen P, et al. Endotoxin-stimulated human monocyte secretion of interleukin-1, tumor necrosis factor-alpha, and prostaglandin-e2 shows stable interindividual differences. Scand J Immunol 1988, 27:705-716.
24. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable major histocompatibility complex class II-associated differences in production of tumor necrosis factor alpha: relevance to genetic predisposition to systemic lupus erythematosus. Proc Natl Acad Sci USA 1990, 87:1233-1237.
25. Kaluza W, Reuss E, Grossmann S, et al. Different transcriptional activity and in vitro TNF-alpha production in psoriasis patients carrying the TNF-alpha 238A promoter polymorphism. J Invest Dermatol 2000, 114:1180-1183.
26. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Nat Acad Sci USA 1997, 94:3195-3199.
27. Hill AVS. Host genetics of infectious diseases: old and new approaches converge. Emerging Infect Dis 1998, 4:695-697.
28. Hill AVS. The immunogenetics of human infectious diseases. Annu Rev Immunol 1998, 16:593-617.
29. Sethi JK, Hotamisligil GS. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 1999, 10:19-29.
30. Mansfield JC, Holden H, Tarlow JK, et al. Novel genetic association between ulcerative-colitis and the antiinflammatory cytokine interleukin-1 receptor antagonist. Gastroenterology 1994, 106:637-642.
31. Grove J, Daly AK, Bassendine MF, Day CP. Association of a tumour necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology 1997, 26:143-146.
32. Bouma G, Crusius JBA, Pool MO, et al. Secretion of tumor-necrosis-factor-alpha and lymphotoxin-alpha in relation to polymorphisms in the tnf genes and hla-dr alleles - relevance for inflammatory bowel-disease. Scand J Immunol 1996, 43:456-463.
33. Huizinga TW, Westendorp RG, Bollen EL, et al. TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients. J Neuroimmunol 1997, 72:149-153.
34. Pociot F, D'Alfonso S, Compasso S, Scorza R, Richiardi PM. Functional analysis of a new polymorphism in the human TNF alpha gene promoter. Scand J Immunol 1995, 42:501-504.
35. Brinkman BMN, Zuijdgeest D, Kaijzel EL, Breedveld FC, Verweij CL. Relevance of the tumor-necrosis-factor-alpha (tnf-alpha) -308-promoter polymorphism in tnf-alpha gene-regulation. J Inflammat 1996, 46:32-41.
36. Wanke C, Gerrior J, Kantaros J, Coakley E, Albrecht M. Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 1999, 13:2099-2103.
37. Lenhard JM, Furfine ES, Jain RG, et al. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro. Antiviral Res 2000, 47:121-129.
38. Dowell P, Flexner C, Kwiterovich PO, Lane MD. Suppression of preadipocyte differentiation and promotion of adipocyte death by HIV protease inhibitors. J Biol Chem 2000, 275:41325-41332.
39. Todd JA. Interpretation of results from genetic studies of multi-factorial diseases. Lancet 1999, 354 Suppl 1:Sl15-16.
40. Wilson AG, Devries N, Pociot F, Digiovine FS, Vanderputte LBA, Duff GW. An allelic polymorphism within the human tumor-necrosis-factor-alpha promoter region is strongly associated with HLA-A1, HLA-B8, and HLA-DR3 alleles. J Exp Med 1993, 177:557-560.
41. Ledru E, Christeff N, Patey O, de Truchis P, Melchior JC, Gougeon ML. Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of human immunodeficiency virus-associated lipodystrophy syndrome. Blood 2000, 95:3191-3198.